Xu Xiaoqing, Ritz Beate, Coleman Anne, Liew Zeyan, Deapen Dennis, Lee Eunjung, Bernstein Leslie, Pinder Rich, Marshall Sarah, Heck Julia E
Department of Epidemiology, Fielding School of Public Health, UCLA, Los Angeles, CA, USA.
Jules Stein Eye Institute, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA.
J Hum Hypertens. 2020 Sep;34(8):568-576. doi: 10.1038/s41371-019-0269-9. Epub 2019 Oct 8.
Sustained and inadequately controlled hypertension can promote the development of age-related macular degeneration (AMD) through multiple biologic pathways. Epidemiologic studies of high blood pressure, antihypertensive therapies, and the risk of AMD thus far have been inconclusive. However, few studies evaluated risks according to the use of different classes of antihypertensive drugs or took combinations of use into account. We performed a prospective cohort study by linking the California Teachers Study (CTS) cohort (N = 88 481) to statewide hospital discharge records up to December 31, 2012. History of high blood pressure, regular use of antihypertensive medications, and comprehensive risk factor information was collected via self-administered questionnaires at baseline in 1995-1996, and information on specific classes of antihypertensive drugs was provided by a subsample of CTS participants who completed a follow-up questionnaire in 2000. We identified 1762 female teachers with AMD during 14.8 years of follow-up on average. Applying Cox proportional hazard regression, we estimated increased risks of AMD among women treated for hypertension at baseline (HR = 1.15, 95% CI: 1.03, 1.30); the magnitude of the association increased with longer duration of antihypertensive treatment. In the subsample with more specific information on type of medication use, we estimated a 45% increased risk of AMD among women receiving diuretics as monotherapy compared to women with medications more potent than diuretics (HR = 1.45, 95% CI 1.10, 1.90). In women treated with a combination of antihypertensive drugs, we observed no increased risk of AMD for any individual class of drugs.
持续性高血压且血压控制不佳可通过多种生物学途径促进年龄相关性黄斑变性(AMD)的发展。迄今为止,关于高血压、抗高血压治疗与AMD风险的流行病学研究尚无定论。然而,很少有研究根据不同类别的抗高血压药物使用情况评估风险,或考虑联合用药情况。我们通过将加利福尼亚教师研究(CTS)队列(N = 88481)与截至2012年12月31日的全州医院出院记录相链接,进行了一项前瞻性队列研究。1995 - 1996年基线时通过自填问卷收集高血压病史、抗高血压药物的常规使用情况以及综合风险因素信息,关于特定类别的抗高血压药物信息由2000年完成随访问卷的CTS参与者子样本提供。在平均14.8年的随访期间,我们确定了1762名患有AMD的女教师。应用Cox比例风险回归分析,我们估计基线时接受高血压治疗的女性患AMD的风险增加(风险比[HR] = 1.15,95%置信区间[CI]:1.03,1.30);这种关联的程度随着抗高血压治疗时间的延长而增加。在有更具体药物使用类型信息的子样本中,我们估计与使用比利尿剂更强效药物的女性相比,接受利尿剂单药治疗的女性患AMD的风险增加45%(HR = 1.45,95% CI 1.10,1.90)。在接受联合抗高血压药物治疗的女性中,我们未观察到任何单个药物类别会增加患AMD的风险。